Delving into the Latest Updates on HTC-867 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

HTC 867

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System Diseases

Active Indication-

Inactive Indication

Schizophrenia

Originator Organization

Pfizer Inc.

Active Organization-

Inactive Organization

Wyeth AB

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to assess the safety and tolerability of ascending single oral doses of HTC-867 in healthy young and elderly subjects. This study will also evaluate the way the drug enters and leaves the blood and tissues over time and how the drug acts on and in the body in a fasted and fed state.

Start Date01 Jan 2009

Sponsor / Collaborator

Wyeth AB

NCT01268124

/ CompletedPhase 1

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HTC-867 Administered Orally to Healthy Japanese Male Subjects

This is a phase 1, randomized (a process that is used to decide whether you will take study drug or a placebo during the study), inpatient study which will assess the safety and tolerability of HTC-867 in healthy male Japanese subjects.

Start Date01 Dec 2008

Sponsor / Collaborator

Wyeth AB

100 Clinical Results associated with HTC-867

Login to view more data

100 Translational Medicine associated with HTC-867

Login to view more data

100 Patents (Medical) associated with HTC-867

Login to view more data

100 Deals associated with HTC-867

Login to view more data